Literature DB >> 9792584

Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions.

N Gupta1, H Gill, G Graeber, H Bishop, J Hurst, T Stephens.   

Abstract

PURPOSE: This study was done to evaluate the diagnostic utility of dynamic positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) imaging in patients with suspected malignant pulmonary lesions. We wanted to test the hypothesis that the rate of FDG uptake (FDG influx constant values) would differentiate malignant from benign lung or mediastinal lesions.
MATERIALS AND METHODS: We performed segmental dynamic PET imaging studies following administration of FDG in 19 patients with indeterminate pulmonary lesions based on chest radiograph and/or CT scans. Patlak analysis was done to compute Ki (FDG influx constant) values and compared with FDG standardized uptake values (SUVs) and histology.
RESULTS: FDG Ki values (mean+/-SD) were significantly greater (p < 0.01) in all 12 malignant lesions (0.029+/-0.02) as compared with 7 benign lesions (0.0024+/-0.0011) with good correlation to the SUV values. Distinct time activity curve patterns were identified in malignant and benign lesions with continued uptake in malignant lesions.
CONCLUSION: Dynamic PET-FDG imaging accurately differentiates malignant from benign pulmonary lesions. In certain cases with equivocal findings on visual analysis and SUV values, dynamic imaging may be further helpful in differentiating benign and malignant lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792584     DOI: 10.1378/chest.114.4.1105

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  24 in total

Review 1.  Molecular imaging for personalized cancer care.

Authors:  Moritz F Kircher; Hedvig Hricak; Steven M Larson
Journal:  Mol Oncol       Date:  2012-03-10       Impact factor: 6.603

2.  Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomas.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Atsushi Tani; Yoriko Kajiya; Shunji Shimaoka; Akio Matsuda; Tatsuyuki Nioh; Tohru Nihara; Toyokuni Suenaga; Sadao Tanaka; Hiroshi Shirahama; Michiyo Higashi; Chihaya Koriyama
Journal:  Eur Radiol       Date:  2011-07-13       Impact factor: 5.315

3.  Solitary pulmonary nodules and masses: a meta-analysis of the diagnostic utility of alternative imaging tests.

Authors:  Paul Cronin; Ben A Dwamena; Aine Marie Kelly; Steven J Bernstein; Ruth C Carlos
Journal:  Eur Radiol       Date:  2008-07-08       Impact factor: 5.315

4.  Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose.

Authors:  Qing Ye; Jing Wu; Yihuan Lu; Mika Naganawa; Jean-Dominique Gallezot; Tianyu Ma; Yaqiang Liu; Lynn Tanoue; Frank Detterbeck; Justin Blasberg; Ming-Kai Chen; Michael Casey; Richard E Carson; Chi Liu
Journal:  Phys Med Biol       Date:  2018-09-06       Impact factor: 3.609

5.  Dynamic changes of FDG uptake and clearance in normal tissues.

Authors:  Gang Cheng; Abass Alavi; Esther Lim; Thomas J Werner; Catherine V Del Bello; Scott R Akers
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

6.  Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer.

Authors:  Wenli Wang; Nancy Y Lee; Jens-Christoph Georgi; Manoj Narayanan; Jose Guillem; Heiko Schöder; John L Humm
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

7.  Positron emission tomography in the evaluation of pulmonary nodules among patients living in a coccidioidal endemic region.

Authors:  Nathaniel Reyes; Oluwole O Onadeko; Maria Del Carmen Luraschi-Monjagatta; Kenneth S Knox; Margaret A Rennels; Travis Kent Walsh; Neil M Ampel
Journal:  Lung       Date:  2014-05-07       Impact factor: 2.584

8.  Performance of integrated FDG-PET/CT for differentiating benign and malignant lung lesions--results from a large prospective clinical trial.

Authors:  Sandra Pauls; Andreas K Buck; Gisela Halter; Felix M Mottaghy; Rainer Muche; Christina Bluemel; Susanne Gerstner; Stefan Krüger; Gerhard Glatting; Ludger Sunder-Plassmann; Peter Möller; Hans-Jürgen Brambs; Sven N Reske
Journal:  Mol Imaging Biol       Date:  2008-01-16       Impact factor: 3.488

9.  Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity.

Authors:  In-Ju Kim; Jung Sub Lee; Seong-Jang Kim; Yong-Ki Kim; Yeon Joo Jeong; Sungmin Jun; Hyun Yul Nam; Ju Sung Kim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-18       Impact factor: 9.236

Review 10.  Limitations of PET for imaging lymphoma.

Authors:  Sally F Barrington; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.